A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
8位分析師一窺Integra Lifesciences的專家展望
Analysts' ratings for Integra Lifesciences (NASDAQ:IART) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
8位分析師提供的分析師對Integra Lifesciences（納斯達克股票代碼：IART）在上個季度的評級從看漲到看跌不等。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Integra Lifesciences, presenting an average target of $33.5, a high estimate of $49.00, and a low estimate of $24.00. Observing a downward trend, the current average is 23.2% lower than the prior average price target of $43.62.
在評估12個月目標股價時，分析師公佈了對Integra Lifesciences的見解，平均目標股價爲33.5美元，最高估計爲49.00美元，低估值爲24.00美元。從下降趨勢來看，目前的平均價格比之前的平均目標價43.62美元低23.2％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
A comprehensive examination of how financial experts perceive Integra...
對金融專家如何看待...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。